Agency Information Collection Activities: Proposed Collection: Public Comment Request; Information Collection Request Title: Substance Use Disorder Treatment and Recovery Loan Repayment Program and the Pediatric Specialty Loan Repayment Program, 32233-32235 [2023-10692]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 97 / Friday, May 19, 2023 / Notices
TABLE 2—REVISED DRAFT PRODUCT- DEPARTMENT OF HEALTH AND
SPECIFIC GUIDANCES FOR DRUG HUMAN SERVICES
PRODUCTS
Health Resources and Services
Administration
Active ingredient(s)
Azelastine hydrochloride; Fluticasone propionate.
Baloxavir marboxil.
Cabozantinib S-malate (multiple reference
listed drugs).
Doxepin hydrochloride.
Fluticasone furoate.
Fluticasone propionate.
Formoterol fumarate.
Formoterol fumarate; Mometasone furoate.
Glycopyrrolate.
Glycopyrrolate; Indacaterol maleate.
Indacaterol maleate.
Ivacaftor.
Lidocaine.
Lithium carbonate (multiple reference listed
drugs).
Mometasone furoate.
Paliperidone palmitate.
Rasagiline mesylate.
For a complete history of previously
published Federal Register notices
related to product-specific guidances, go
to https://www.regulations.gov and
enter Docket No. FDA–2007–D–0369.
These draft guidances are being
issued consistent with FDA’s good
guidance practices regulation (21 CFR
10.115). These draft guidances, when
finalized, will represent the current
thinking of FDA on, among other things,
the product-specific design of BE
studies to support ANDAs. They do not
establish any rights for any person and
are not binding on FDA or the public.
You can use an alternative approach if
it satisfies the requirements of the
applicable statutes and regulations.
IV. Paperwork Reduction Act of 1995
FDA tentatively concludes that these
draft guidances contain no collection of
information. Therefore, clearance by the
Office of Management and Budget under
the Paperwork Reduction Act of 1995 is
not required.
ddrumheller on DSK120RN23PROD with NOTICES1
V. Electronic Access
Persons with access to the internet
may obtain the draft guidance at https://
www.fda.gov/drugs/guidancecompliance-regulatory-information/
guidances-drugs, https://www.fda.gov/
regulatory-information/search-fdaguidance-documents, or https://
www.regulations.gov.
Dated: May 15, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–10710 Filed 5–18–23; 8:45 am]
BILLING CODE 4164–01–P
VerDate Sep<11>2014
18:30 May 18, 2023
Jkt 259001
Agency Information Collection
Activities: Proposed Collection: Public
Comment Request; Information
Collection Request Title: Substance
Use Disorder Treatment and Recovery
Loan Repayment Program and the
Pediatric Specialty Loan Repayment
Program
Health Resources and Services
Administration (HRSA), Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
In compliance with the
Paperwork Reduction Act of 1995,
HRSA submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period. OMB may act on
HRSA’s ICR only after the 30-day
comment period for this notice has
closed.
SUMMARY:
Comments on this ICR should be
received no later than June 20, 2023.
ADDRESSES: Written comments and
recommendations for the proposed
information collection should be sent
within 30 days of publication of this
notice to www.reginfo.gov/public/do/
PRAMain. Find this particular
information collection by selecting
‘‘Currently under Review—Open for
Public Comments’’ or by using the
search function.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email
Samantha Miller, the HRSA Information
Collection Clearance Officer, at
paperwork@hrsa.gov or call (301) 443–
1984.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title:
Substance Use Disorder Treatment and
Recovery Loan Repayment Program and
the Pediatric Specialty Loan Repayment
Program, OMB No. 0906–0058—
Revision
Abstract: The Consolidated
Appropriations Act, 2023 included
$40,000,000 for the Substance Use
Disorder Treatment and Recovery
(STAR) Loan Repayment Program (LRP).
This funding will allow HRSA to
provide the repayment of education
loans for individuals working in a fullDATES:
PO 00000
Frm 00058
Fmt 4703
Sfmt 4703
32233
time substance use disorder treatment
job that involves direct patient care in
either a Health Professional Shortage
Area (HPSA) designated for Mental
Health, or a county where the average
drug overdose death rate exceeds the
national average. The Further
Consolidated Appropriations Act, 2022
and the Consolidated Appropriations
Act, 2023 included $5,000,000 and
$10,000,000, respectively, for HRSA to
award eligible individuals through the
Pediatric Specialty LRP. This funding
will allow HRSA to provide the
repayment of education loans to
pediatric medical subspecialist,
pediatric surgical specialist, and child
and adolescent mental and behavioral
health care providers working full-time
in or serving a HPSA, medically
underserved area (MUA), or medically
underserved population (MUP). This
information collection request adds the
Pediatric Specialty LRP and relevant
forms.
The Department of Health and Human
Services agrees to make payment of up
to $250,000 for the repayment of eligible
educational loans in return for 6 years
of service obligation through the STAR
LRP, and up to $100,000 in return for
3 years of service obligation through the
Pediatric Specialty LRP. The forms used
by the STAR LRP and the Pediatric
Specialty LRP include the following: the
LRP Application, the Authorization for
Disclosure of Loan Information form,
the Privacy Act Release Authorization
form, and the electronic Employment
Verification form, if applicable. The
forms collect information needed for
selecting participants and repaying
eligible educational loans.
Eligible disciplines for the STAR LRP
and the Pediatric Specialty LRP include,
but are not limited to physicians,
psychologists, psychiatric nurses,
marriage and facility therapists, social
workers, counselors, and substance use
disorder counselors. Additional
providers that are exclusively eligible
for the Pediatric Specialty LRP include
pediatric medical subspecialty,
pediatric surgical specialty, and child
and adolescent mental and behavioral
health care providers.
Eligible facilities or sites for the STAR
LRP and Pediatric Specialty LRP
programs include, but are not limited to:
School-Based Clinics, Community
Health Centers, Inpatient Programs/
Rehabilitation Centers, Federally
Qualified Health Centers, Centers for
Medicare & Medicaid Services-approved
Critical Access Hospitals, American
Indian Health Facilities (Indian Health
Service Facilities, Tribally-Operated 638
Health Programs, and Urban Indian
Health Programs), inpatient
E:\FR\FM\19MYN1.SGM
19MYN1
32234
Federal Register / Vol. 88, No. 97 / Friday, May 19, 2023 / Notices
rehabilitation centers, and psychiatric
facilities. STAR LRP facilities must be
located in a mental health HPSA or a
county where the average drug overdose
death rate exceeds the national average.
Pediatric Specialty LRP sites must
provide pediatric medical subspecialty
care, pediatric surgical specialty care, or
child and adolescent mental and
behavioral health care in or to a HPSA,
MUA, or MUP. HRSA will approve and
activate sites for the Pediatric Specialty
LRP if:
(1) The facility is already approved for
the National Health Service Corps,
Nurse Corps, or STAR LRP and located
in or serves a HPSA, MUA, or MUP; or
(2) During the Pediatric Specialty LRP
application cycle, the facility submits to
HRSA the site type and the point of
contact(s) to PS_LRP_Sites@hrsa.gov.
HRSA will review and approve new
facilities during the respective
application cycle for the STAR LRP and
the Pediatric Specialty LRP. New
facilities must submit to HRSA the
facility type and the recruitment
contact(s). HRSA will use the
information collected to determine
eligibility of the facility for the
assignment of health professionals and
to verify the need for clinicians. Note:
Despite the similarity in the titles, the
STAR LRP is not the existing National
Health Service Corps Substance Use
Disorder LRP (OMB #0915–0127),
which is authorized under Title III of
the Public Health Service Act. The
STAR LRP is authorized under Title VII
of the Public Health Service Act and has
different service requirements, loan
repayment protocols, and authorized
employment facilities.
Need and Proposed Use of the
Information: The need and purpose of
this information collection is to obtain
information that is used to assess an
applicant’s eligibility and qualifications
for the STAR LRP and the Pediatric
Specialty LRP, and to obtain
information for eligible facilities or
sites. Clinicians interested in
participating in the STAR LRP or the
Pediatric Specialty LRP must apply to
the applicable program to participate.
Additionally, health care facilities
located in a high overdose death rate
area or mental health HPSAs must
submit the facility type and the site
point(s) of contact(s) for HRSA to
determine the facility’s eligibility to
participate in the STAR LRP. Similarly,
sites located in or serving a HPSA,
MUA, or MUP must submit the site type
and the site point(s) of contact(s) for
HRSA to determine the sites’ eligibility
to participate in the Pediatric Specialty
LRP. The STAR LRP and the Pediatric
Specialty LRP application asks for
personal, professional, and financial
information needed to determine the
applicant’s eligibility to participate in
either of the programs. In addition,
applicants must provide information
regarding the loans for which repayment
is being requested.
A 60-day notice published in the
Federal Register on March 8, 2023, vol.
88, No. 45; pp. 14373–74. There were no
public comments.
Likely Respondents: Licensed
medical, mental, and behavioral health
providers who are employed or seeking
employment and are interested in
serving underserved populations; and
health care facilities or sites interested
in participating in the STAR LRP and/
or the Pediatric Specialty LRP and
becoming an approved facility or site.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating, and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the tables below.
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS FOR THE STAR LRP
Number of
respondents
Form name
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total
responses
Total
burden
hours
STAR LRP Application .........................................................
Authorization for Disclosure of Loan Information Form .......
Privacy Act Release Authorization Form .............................
Employment Verification Form .............................................
3,200
3,200
3,200
3,200
1
1
1
1
3,200
3,200
3,200
3,200
.50
.50
.50
.50
1,600
1,600
1,600
1,600
Total ..............................................................................
12,800
........................
12,800
........................
6,400
TOTAL ESTIMATED ANNUALIZED BURDEN HOURS FOR THE PEDIATRIC SPECIALTY LRP
Number of
respondents
ddrumheller on DSK120RN23PROD with NOTICES1
Form name
Number of
responses per
respondent
Average
burden per
response
(in hours)
Total
responses
Total
burden
hours
Pediatric Specialty LRP Application ....................................
Authorization for Disclosure of Loan Information Form .......
Privacy Act Release Authorization Form .............................
Employment Verification Form .............................................
500
500
500
500
1
1
1
1
500
500
500
500
.50
.50
.50
.50
250
250
250
250
Total ..............................................................................
2,000
........................
2,000
........................
1,000
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
VerDate Sep<11>2014
18:30 May 18, 2023
Jkt 259001
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
PO 00000
Frm 00059
Fmt 4703
Sfmt 4703
use of automated collection techniques
or other forms of information
E:\FR\FM\19MYN1.SGM
19MYN1
Federal Register / Vol. 88, No. 97 / Friday, May 19, 2023 / Notices
technology to minimize the information
collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023–10692 Filed 5–18–23; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director, National
Institutes of Health; Notice of Meeting
ddrumheller on DSK120RN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Advisory Committee to
the Director, National Institutes of
Health.
This will be a hybrid meeting held inperson and virtually and will be open to
the public as indicated below. Given the
capacity constraints of the venue, the
public is strongly encouraged to attend
virtually via NIH videocast. Individuals
who plan to attend in-person or view
the virtual meeting and need special
assistance or other reasonable
accommodations, should notify the
Contact Person listed below in advance
of the meeting. The meeting can be
accessed from the NIH Videocast at the
following link: https://
videocast.nih.gov/.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Advisory Committee
to the Director, National Institutes of Health.
Date: June 8, 2023.
Open: 9:00 a.m. to 4:45 p.m.
Agenda: Performing the Duties of the NIH
Director’s Report; NIH Public Access Plan;
Cancer Moonshot; Addressing the Mental
Health Crisis through Research; Addressing
the Public Health Threat of Post-Acute
Sequelae of SARS CoV–2 Infection (PASC)—
NIH RECOVER Initiative: Briefing for the
Advisory Council to the Director (ACD); The
Foundation for the National Institutes of
Health (FNIH); Other Business of the
Committee.
Date: June 8, 2023.
Closed: 4:55 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Date: June 9, 2023.
VerDate Sep<11>2014
18:30 May 18, 2023
Jkt 259001
Open: 9:00 a.m. to 3:00 p.m.
Agenda: HeLA Genome Data Access
Working Group: Data Access Requests; NIHwide Collaborative Initiative on Climate
Change and Health; Clinical Trial
Stewardship; Accessibility Update; Update
from the ACD Working Group on Catalyzing
the Development and Use of Novel
Alternative Methods to Advance Biomedical
Research; Update from the ACD Working
Group on Re-envisioning NIH-Supported
Postdoctoral Training; Other Business of the
Committee.
Place: National Institutes of Health,
Building 1, Wilson Hall, One Center Drive,
Bethesda, MD 20892.
Contact Person: Cyndi Burrus-Shaw, Staff
Assistant, National Institutes of Health,
Office of the Director, One Center Drive,
Building 1, Room 126, Bethesda, MD 20892,
301–496–2433, shawcy@od.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors attending a meeting on
campus or at an off-campus federal facility
will be asked to show one form of
identification (for example, a governmentissued photo ID, driver’s license, or passport)
and to state the purpose of their visit.
Information is also available on the
Institute’s/Center’s home page: https://
acd.od.nih.gov, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.14, Intramural Research
Training Award; 93.22, Clinical Research
Loan Repayment Program for Individuals
from Disadvantaged Backgrounds; 93.232,
Loan Repayment Program for Research
Generally; 93.39, Academic Research
Enhancement Award; 93.936, NIH Acquired
Immunodeficiency Syndrome Research Loan
Repayment Program; 93.187, Undergraduate
Scholarship Program for Individuals from
Disadvantaged Backgrounds, National
Institutes of Health, HHS)
Dated: May 15, 2023.
David W. Freeman,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–10689 Filed 5–18–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
32235
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental and
Craniofacial Research; Notice of
Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: NIDCR Special Grants
Review Committee.
Date: June 29–30, 2023.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Dental and
Craniofacial Research, 6701 Democracy
Blvd., Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Thomas John O’Farrell,
Ph.D., Scientific Review Officer, Scientific
Review Branch, Division of Extramural
Activities, National Institute of Dental and
Craniofacial Research, 6701 Democracy
Blvd., Bethesda, MD 20892, 301–402–8559,
tom.ofarrell@nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.121, Oral Diseases and
Disorders Research, National Institutes of
Health, HHS)
Dated: May 15, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–10656 Filed 5–18–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Notice of Meeting
Pursuant to Public Law 92–463,
notice is hereby given that the
Substance Abuse and Mental Health
Services Administration’s (SAMHSA)
Center for Substance Abuse Prevention’s
(CSAP) Drug Testing Advisory Board
(DTAB) will convene via web
conference on June 13, 2023, from 9:30
a.m. EST to 5:00 p.m. EST.
E:\FR\FM\19MYN1.SGM
19MYN1
]]>Agencies
[Federal Register Volume 88, Number 97 (Friday, May 19, 2023)]
[Notices]
[Pages 32233-32235]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10692]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Proposed Collection:
Public Comment Request; Information Collection Request Title: Substance
Use Disorder Treatment and Recovery Loan Repayment Program and the
Pediatric Specialty Loan Repayment Program
AGENCY: Health Resources and Services Administration (HRSA), Department
of Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with the Paperwork Reduction Act of 1995, HRSA
submitted an Information Collection Request (ICR) to the Office of
Management and Budget (OMB) for review and approval. Comments submitted
during the first public review of this ICR will be provided to OMB. OMB
will accept further comments from the public during the review and
approval period. OMB may act on HRSA's ICR only after the 30-day
comment period for this notice has closed.
DATES: Comments on this ICR should be received no later than June 20,
2023.
ADDRESSES: Written comments and recommendations for the proposed
information collection should be sent within 30 days of publication of
this notice to www.reginfo.gov/public/do/PRAMain. Find this particular
information collection by selecting ``Currently under Review--Open for
Public Comments'' or by using the search function.
FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance
requests submitted to OMB for review, email Samantha Miller, the HRSA
Information Collection Clearance Officer, at [email protected] or call
(301) 443-1984.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title: Substance Use Disorder
Treatment and Recovery Loan Repayment Program and the Pediatric
Specialty Loan Repayment Program, OMB No. 0906-0058--Revision
Abstract: The Consolidated Appropriations Act, 2023 included
$40,000,000 for the Substance Use Disorder Treatment and Recovery
(STAR) Loan Repayment Program (LRP). This funding will allow HRSA to
provide the repayment of education loans for individuals working in a
full-time substance use disorder treatment job that involves direct
patient care in either a Health Professional Shortage Area (HPSA)
designated for Mental Health, or a county where the average drug
overdose death rate exceeds the national average. The Further
Consolidated Appropriations Act, 2022 and the Consolidated
Appropriations Act, 2023 included $5,000,000 and $10,000,000,
respectively, for HRSA to award eligible individuals through the
Pediatric Specialty LRP. This funding will allow HRSA to provide the
repayment of education loans to pediatric medical subspecialist,
pediatric surgical specialist, and child and adolescent mental and
behavioral health care providers working full-time in or serving a
HPSA, medically underserved area (MUA), or medically underserved
population (MUP). This information collection request adds the
Pediatric Specialty LRP and relevant forms.
The Department of Health and Human Services agrees to make payment
of up to $250,000 for the repayment of eligible educational loans in
return for 6 years of service obligation through the STAR LRP, and up
to $100,000 in return for 3 years of service obligation through the
Pediatric Specialty LRP. The forms used by the STAR LRP and the
Pediatric Specialty LRP include the following: the LRP Application, the
Authorization for Disclosure of Loan Information form, the Privacy Act
Release Authorization form, and the electronic Employment Verification
form, if applicable. The forms collect information needed for selecting
participants and repaying eligible educational loans.
Eligible disciplines for the STAR LRP and the Pediatric Specialty
LRP include, but are not limited to physicians, psychologists,
psychiatric nurses, marriage and facility therapists, social workers,
counselors, and substance use disorder counselors. Additional providers
that are exclusively eligible for the Pediatric Specialty LRP include
pediatric medical subspecialty, pediatric surgical specialty, and child
and adolescent mental and behavioral health care providers.
Eligible facilities or sites for the STAR LRP and Pediatric
Specialty LRP programs include, but are not limited to: School-Based
Clinics, Community Health Centers, Inpatient Programs/Rehabilitation
Centers, Federally Qualified Health Centers, Centers for Medicare &
Medicaid Services-approved Critical Access Hospitals, American Indian
Health Facilities (Indian Health Service Facilities, Tribally-Operated
638 Health Programs, and Urban Indian Health Programs), inpatient
[[Page 32234]]
rehabilitation centers, and psychiatric facilities. STAR LRP facilities
must be located in a mental health HPSA or a county where the average
drug overdose death rate exceeds the national average. Pediatric
Specialty LRP sites must provide pediatric medical subspecialty care,
pediatric surgical specialty care, or child and adolescent mental and
behavioral health care in or to a HPSA, MUA, or MUP. HRSA will approve
and activate sites for the Pediatric Specialty LRP if:
(1) The facility is already approved for the National Health
Service Corps, Nurse Corps, or STAR LRP and located in or serves a
HPSA, MUA, or MUP; or
(2) During the Pediatric Specialty LRP application cycle, the
facility submits to HRSA the site type and the point of contact(s) to
[email protected].
HRSA will review and approve new facilities during the respective
application cycle for the STAR LRP and the Pediatric Specialty LRP. New
facilities must submit to HRSA the facility type and the recruitment
contact(s). HRSA will use the information collected to determine
eligibility of the facility for the assignment of health professionals
and to verify the need for clinicians. Note: Despite the similarity in
the titles, the STAR LRP is not the existing National Health Service
Corps Substance Use Disorder LRP (OMB #0915-0127), which is authorized
under Title III of the Public Health Service Act. The STAR LRP is
authorized under Title VII of the Public Health Service Act and has
different service requirements, loan repayment protocols, and
authorized employment facilities.
Need and Proposed Use of the Information: The need and purpose of
this information collection is to obtain information that is used to
assess an applicant's eligibility and qualifications for the STAR LRP
and the Pediatric Specialty LRP, and to obtain information for eligible
facilities or sites. Clinicians interested in participating in the STAR
LRP or the Pediatric Specialty LRP must apply to the applicable program
to participate. Additionally, health care facilities located in a high
overdose death rate area or mental health HPSAs must submit the
facility type and the site point(s) of contact(s) for HRSA to determine
the facility's eligibility to participate in the STAR LRP. Similarly,
sites located in or serving a HPSA, MUA, or MUP must submit the site
type and the site point(s) of contact(s) for HRSA to determine the
sites' eligibility to participate in the Pediatric Specialty LRP. The
STAR LRP and the Pediatric Specialty LRP application asks for personal,
professional, and financial information needed to determine the
applicant's eligibility to participate in either of the programs. In
addition, applicants must provide information regarding the loans for
which repayment is being requested.
A 60-day notice published in the Federal Register on March 8, 2023,
vol. 88, No. 45; pp. 14373-74. There were no public comments.
Likely Respondents: Licensed medical, mental, and behavioral health
providers who are employed or seeking employment and are interested in
serving underserved populations; and health care facilities or sites
interested in participating in the STAR LRP and/or the Pediatric
Specialty LRP and becoming an approved facility or site.
Burden Statement: Burden in this context means the time expended by
persons to generate, maintain, retain, disclose, or provide the
information requested. This includes the time needed to review
instructions; to develop, acquire, install, and utilize technology and
systems for the purpose of collecting, validating, and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information; to search data sources; to complete and
review the collection of information; and to transmit or otherwise
disclose the information. The total annual burden hours estimated for
this ICR are summarized in the tables below.
Total Estimated Annualized Burden Hours for the STAR LRP
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total burden per Total burden
Form name respondents responses per responses response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
STAR LRP Application............ 3,200 1 3,200 .50 1,600
Authorization for Disclosure of 3,200 1 3,200 .50 1,600
Loan Information Form..........
Privacy Act Release 3,200 1 3,200 .50 1,600
Authorization Form.............
Employment Verification Form.... 3,200 1 3,200 .50 1,600
-------------------------------------------------------------------------------
Total....................... 12,800 .............. 12,800 .............. 6,400
----------------------------------------------------------------------------------------------------------------
Total Estimated Annualized Burden Hours for the Pediatric Specialty LRP
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total burden per Total burden
Form name respondents responses per responses response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Pediatric Specialty LRP 500 1 500 .50 250
Application....................
Authorization for Disclosure of 500 1 500 .50 250
Loan Information Form..........
Privacy Act Release 500 1 500 .50 250
Authorization Form.............
Employment Verification Form.... 500 1 500 .50 250
-------------------------------------------------------------------------------
Total....................... 2,000 .............. 2,000 .............. 1,000
----------------------------------------------------------------------------------------------------------------
HRSA specifically requests comments on (1) the necessity and
utility of the proposed information collection for the proper
performance of the agency's functions, (2) the accuracy of the
estimated burden, (3) ways to enhance the quality, utility, and clarity
of the information to be collected, and (4) the use of automated
collection techniques or other forms of information
[[Page 32235]]
technology to minimize the information collection burden.
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2023-10692 Filed 5-18-23; 8:45 am]
BILLING CODE 4165-15-P
